Journal
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Volume 18, Issue 8, Pages 369-378Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/adt.2020.987
Keywords
mesoporous hollow silica nanospheres; gelatin; type-2 diabetes; glimepiride; pharmacodynamic
Funding
- National Natural Science Foundation of China [81770459, 81970369]
- Natural Science Foundation Guidance Plan of Liaoning Province [201602301]
Ask authors/readers for more resources
In this study, we prepared gelatin-coated mesoporous hollow silica nanospheres (GSN) as a drug carrier to improve the water solubility and regulate the release rate of glimepiride (GLM). GLM was loaded into GSN by an absorption method, and drug-loaded samples (GLM-GSN) were characterized by differential scanning calorimeter (DSC) and X-ray diffraction (XRD). Cellular uptake and in vivo intestinal uptake experiments were performed in rats. In addition, the studies of in-vitro drug dissolution, pharmacokinetics, and pharmacodynamic experiments also were performed. GLM-GSN showed excellent drug loading (39.7% +/- 0.7%) and sustained GLM release. The state of GLM in GSN was amorphous according to DSC and XRD results. Cellular uptake and in vivo intestinal uptake experiments indicated that GSN could be effectively absorbed, and an MTT experiment demonstrated that GSN had good biocompatibility. Furthermore, the GLM-GSN had a higher bioavailability in pharmacokinetics experiments and a prominent hypoglycemic effect on type-2 diabetes model rats in pharmacodynamic experiments. This study clearly shows that GSN is a promising platform for delivering GLM for the treatment of type-2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available